Registration Dossier

Administrative data

Description of key information

Two acute oral studies are available (BASF AG, Report No XXIV/62, 08 Oct 1974; BASF AG, Report No XXIV/61, 08 Oct 1974) all comparable to OECD guideline 401 but were conducted prior to the existence of guidelines. The LD50 was determined in the 2 studies to be higher than 10000 mg/kg bw.

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed

Acute toxicity: via dermal route

Endpoint conclusion

Additional information

In the 2 available studies, rat (Sprague-Dawley; 5 animals per sex) were treated (gavage) with test substance suspended in 0.5% aqueous CMC (concentration of test substance in vehicle: 35%). Daily check for mortality and clinical signs were performed up to 14 days after treatment, as well as pathological analysis of death and survivors animals at necropsy.

 

No mortality, clinical signs or abnormalities were observed at dose levels up to 10000 mg/kg bw with rats. The urine and feces were discolored during the first days post substance application. The LD50 was determined to be in excess of 10000 mg/kg bw in rats.

The acute dermal and inhalation toxicity was not tested.

Justification for classification or non-classification

Because the LD50 exceeds the classification limit of 5,000 mg/kg bw (GHS) and 2,000 mg/kg bw (67/548/EEC), a classification is not warranted.